Skip to main content

Advertisement

SpringerLink
Log in

Cost of transfusion-dependent myelodysplastic syndrome (MDS) from a German payer’s perspective

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

No curative treatment exists for patients with myelodysplastic syndrome (MDS) besides allogeneic stem cell transplantation. Hence, palliative treatment is provided for a life time accruing high health care cost. As no study in cost of MDS exists in Germany, the objective of this study was to assess and analyze costs of transfusion-dependent low/intermediate-1-risk MDS in Germany from a payers’ perspective. From seven centers, 116 low/intermediate-1-risk transfusion-dependent MDS patients with and without isolated 5q-deletion were identified. Claims data and patient records of the previous 5 years were used to collect health care utilization data retrospectively. Publicly available tariff books and remuneration schemes were applied to evaluate mean costs per year in Euro with 2007 as base year. The annual cost of MDS patients was estimated at €14,883. Subgroup analyses showed differences in patient’s characteristics and outcomes among patients treated at a hospital-based vs. an office-based setting. Patients treated at the hospital-based registry show higher cost, whereas the reasons for that still need to be detected. Overall, per annum direct costs range from €12,543 (SD 12,967) to €24,957 (SD 36,399) in different subgroups of patients. In both groups, patients with 5q-deletion use more medication than those without deletion. Mean costs for medication in the office-based setting are €5,902 for patients with isolated 5q-deletion vs. €3,932 for patients with no deletion, respectively. MDS leads to a high health care utilization and resulting costs for the health care system which requires a detailed analysis of underlying services.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Germing U, Strupp C, Kundgen A, Bowen D, Aul C, Haas R et al (2004) No increase in age-specific incidence of myelodysplastic syndromes. Haematologica 89:905–910

    PubMed  Google Scholar 

  2. Ma X, Does M, Raza A, Mayne ST (2007) Myelodysplastic syndromes: incidence and survival in the United States. Cancer 109:1536–1542

    Article  PubMed  Google Scholar 

  3. Germing U, Strupp C, Kuendgen A, Isa S, Knipp S, Hildebrandt B et al (2006) Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes. Haematologica 91:1596–1604

    PubMed  Google Scholar 

  4. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J et al (2000) The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting–Airlie House, Virginia, November, 1997. Hematol J 1:53–66

    Article  CAS  PubMed  Google Scholar 

  5. Brunning RD, Orazi A, Germing U et al (2008) Myelodysplastic syndromes/neoplasms, overview. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (eds) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edn. IARC Press, Lyon

    Google Scholar 

  6. Haase D, Germing U, Schanz J, Pfeilstocker M, Nosslinger T, Hildebrandt B et al (2007) New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 110:4385–4395

    Article  CAS  PubMed  Google Scholar 

  7. Heim S, Mitelman F (1986) Chromosome abnormalities in the myelodysplastic syndromes. Clin Haematol 15:1003–1021

    CAS  PubMed  Google Scholar 

  8. Sole F, Espinet B, Sanz GF, Cervera J, Calasanz MJ, Luno E et al (2000) Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes. Grupo Cooperativo Espanol de Citogenetica Hematologica. Br J Haematol 108:346–356

    Article  CAS  PubMed  Google Scholar 

  9. Boultwood J, Lewis S, Wainscoat JS (1994) The 5q-syndrome. Blood 84:3253–3260

    CAS  PubMed  Google Scholar 

  10. Giagounidis AA, Germing U, Haase S, Hildebrandt B, Schlegelberger B, Schoch C et al (2004) Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31. Leukemia 18:113–119

    Article  CAS  PubMed  Google Scholar 

  11. Goss T, Szende A, Schaefer C, Knight R, Heptinstall K, Lübbert M et al (2007) Value of transfusion free living in MDS: results of health utility reviews with patients. Leuk Res 31:S105–S106

    Article  Google Scholar 

  12. Malcovati L, Della Porta M, Pascutto C, Invernizzi R, Passamonti F, Arcaini L et al (2005) The effect of transfusion dependency and secondary iron overload on survival of patients with myelodysplastic syndrome. Blood (ASH Annual Meeting Abstracts) 106:791

    Google Scholar 

  13. Malcovati L, Porta MG, Pascutto C, Invernizzi R, Boni M, Travaglino E et al (2005) Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 23:7594–7603

    Article  PubMed  Google Scholar 

  14. Frytag JR, Henk H, Nelson M, DeCastro C (2005) Economic burden of transfusion dependence in patients with myelodysplastic syndromes. Proc Annu Meet Am Soc Clin Oncol 23:6064

    Google Scholar 

  15. Gupta P, LeRoy SC, Luikart SD, Bateman A, Morrison VA (1999) Long-term blood product transfusion support for patients with myelodysplastic syndromes (MDS): cost analysis and complications. Leuk Res 23:953–959

    Article  CAS  PubMed  Google Scholar 

  16. Gattermann N (2007) Guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload. Leuk Res 31(Suppl 3):S10–S15

    Article  CAS  PubMed  Google Scholar 

  17. Jensen PD, Heickendorff L, Pedersen B, dix-Hansen K, Jensen FT, Christensen T et al (1996) The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload. Br J Haematol 94:288–299

    Article  CAS  PubMed  Google Scholar 

  18. Propper RD, Cooper B, Rufo RR, Nienhuis AW, Andersen WF, Bunn HF et al (1977) Continuous subcutaneous administration of deferox-amine in patients with iron overload. N Engl J Med 297:418–423

    Article  CAS  PubMed  Google Scholar 

  19. Park S, Grabar S, Kelaidi C, Beyne-Rauzy O, Picard F, Bardet V et al (2008) Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood 111:574–582

    Article  CAS  PubMed  Google Scholar 

  20. Miller KB, Kim HT, Greenberg P, van der Jagt R, Bennett JM, Tallman MS et al (2004) Phase III prospective randomized trial of EPO with or without G-CSF versus supportive therapy alone in the treatment of myelodysplastic syndromes (MDS): results of the ECOG-CLSG trial (E1996). Blood (ASH Annual Meeting Abstracts) 104:70

    Google Scholar 

  21. Jadersten M, Montgomery SM, Dybedal I, Porwit-MacDonald A, Hellstrom-Lindberg E (2005) Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF. Blood 106:803–811

    Article  PubMed  Google Scholar 

  22. Thompson JA, Gilliland DG, Prchal JT, Bennett JM, Larholt K, Nelson RA et al (2000) Effect of recombinant human erythropoietin combined with granulocyte/macrophage colony-stimulating factor in the treatment of patients with myelodysplastic syndrome. Blood 95:1175–1179

    CAS  PubMed  Google Scholar 

  23. Hellstrom-Lindberg E, Gulbrandsen N, Lindberg G, Ahlgren T, Dahl IM, Dybedal I et al (2003) A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol 120:1037–1046

    Article  CAS  PubMed  Google Scholar 

  24. Hellstrom-Lindberg E, Ahlgren T, Beguin Y, Carlsson M, Carneskog J, Dahl MD et al (1998) Treatment of anemia in myelodysplastic syn-dromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. Blood 92:68–75

    CAS  PubMed  Google Scholar 

  25. Mannone L, Gardin C, Quarre MC, Bernard JF, Vassilieff D, Ades L et al (2006) High-dose darbepoetin alpha in the treatment of anemia in lower risk myelodysplastic syndrome: results of a phase II study. Br J Haematol 133:513–519

    Article  CAS  PubMed  Google Scholar 

  26. Dimopoulos M, Spencer A, Attal M, Prince M, Harousseau JL, Dmoszynska A et al (2007) Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma. N Engl J Med 357:2123–2132

    Article  CAS  PubMed  Google Scholar 

  27. List A, Baker AF, Green S, Bellamy W (2006) Lenalidomide: targeted anemia therapy for myelodysplastic syndrome. Cancer Control 13:4–11

    PubMed  Google Scholar 

  28. List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E et al (2006) Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 355:1456–1465

    Article  CAS  PubMed  Google Scholar 

  29. Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA et al (2007) Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America. N Engl J Med 357:2133–2142

    Article  CAS  PubMed  Google Scholar 

  30. Fenaux P, Mufti GJ, Santini V, Finelli C, Giagounidis A, Schoch R et al (2007) Azacitidine (AZA) treatment prolongs overall survival (OS) in higher-risk MDS patients compared with conventional care regimens (CCR): results of the AZA-001 phase III study. Blood (ASH Annual Meeting Abstracts) 110:817

    Google Scholar 

  31. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A et al (2009) Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 10:223–232

    Article  CAS  PubMed  Google Scholar 

  32. Brechignac S, Hellstrom-Lindberg E, Bowen D, DeWitte T, Cazzola M, Fenaux P (2004) Quality of Life and Economic Impact of Red Blood Cell (RBC) Transfusions on Patients with Myelodysplastic Syndromes (MDS). Blood 104:263b

    Article  Google Scholar 

  33. Casadevall N, Durieux P, Dubois S, Hemery F, Lepage E, Quarre MC et al (2004) Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. Blood 104:321–327

    Article  CAS  PubMed  Google Scholar 

  34. Frytag JR, Henk H, De Castro CM, Halpern R (2007) Cost of transfusion dependency among managed care patients with myelodysplastic syndromes. Leuk Res 31:S111–S112

    Article  Google Scholar 

  35. Goss T, Szende A, Schaefer C, Totten PJ, Knight R, Jädersten M et al (2006) Cost effectiveness of lenalidomide in the treatment of transfusion-dependent myelodysplastic syndromes in the United States. Cancer Control 13:17–25

    PubMed  Google Scholar 

  36. Hodgson TA (1988) Annual costs of illness versus lifetime costs of illness and implications of structual change. Drug Inf J 22:323–341

    Google Scholar 

Download references

Acknowledgments

This research was supported by an unrestricted educational grant by Celgene GmbH, Germany.

Author information

Authors and Affiliations

  1. Center for Health Economics, Leibniz University of Hanover, Hannover, Germany

    Felicitas Kühne, Thomas Mittendorf & Johann Matthias von der Schulenburg

  2. Department of Haematology, Oncology and Clinical Immunology, Centre for Haematology and Oncology, University of Düsseldorf, Düsseldorf, Germany

    Ulrich Germing

  3. Private-based oncology practice, Frankfurt, Germany

    Hans Tesch

  4. Private-based oncology practice, Aachen, Germany

    Reiner Weinberg

  5. Private-based oncology practice, Mönchengladbach, Germany

    Ulrich Grabenhorst

  6. Private-based oncology practice, Hamburg, Germany

    Andreas Mohr

  7. Innovation Oncology Research & Consulting (IORC) GmbH, Hamburg, Germany

    Rainer Lipp

  8. Ladenstr.13, 39164, Wanzleben, Germany

    Felicitas Kühne

Authors
  1. Felicitas Kühne
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas Mittendorf
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ulrich Germing
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hans Tesch
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Reiner Weinberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ulrich Grabenhorst
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Andreas Mohr
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Rainer Lipp
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Johann Matthias von der Schulenburg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Felicitas Kühne.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kühne, F., Mittendorf, T., Germing, U. et al. Cost of transfusion-dependent myelodysplastic syndrome (MDS) from a German payer’s perspective. Ann Hematol 89, 1239–1247 (2010). https://doi.org/10.1007/s00277-010-1017-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-010-1017-y

Keywords

Search

Navigation